Cargando…

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

BACKGROUND: Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chia-Yu, Yeh, Yung-Hsin, Chan, Yi-Hsin, Liu, Jia-Rou, Chang, Shang-Hung, Lee, Hsin-Fu, Wu, Lung-Sheng, Yen, Kun-Chi, Kuo, Chi-Tai, See, Lai-Chu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735601/ https://www.ncbi.nlm.nih.gov/pubmed/29258504 http://dx.doi.org/10.1186/s12933-017-0640-5

Ejemplares similares

Young Male Patients with Atrial Fibrillation and CHA(2)DS(2)-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study
por: Chan, Yi-Hsin, et al.
Publicado: (2016)

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
por: Lee, Hsin-Fu, et al.
Publicado: (2020)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Lee, Hsin-Fu, et al.
Publicado: (2023)

The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018)

Atrial fibrillation and its arrhythmogenesis associated with insulin resistance
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Aldehyde Dehydrogenase 2 Ameliorates Chronic Alcohol Consumption-Induced Atrial Fibrillation through Detoxification of 4-HNE
por: Hsu, Lung-An, et al.
Publicado: (2020)

Association evidence of CCTTT repeat polymorphism in the iNOS promoter and the risk of atrial fibrillation in Taiwanese
por: Hsu, Lung-An, et al.
Publicado: (2017)

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan
por: Wu, Lung-Sheng, et al.
Publicado: (2016)

Familial aggregation of myocardial infarction and coaggregation of myocardial infarction and autoimmune disease: a nationwide population-based cross-sectional study in Taiwan
por: Wang, Chun-Li, et al.
Publicado: (2019)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

MMP9 Rs3918242 Polymorphism Affects Tachycardia-Induced MMP9 Expression in Cultured Atrial-Derived Myocytes but Is Not a Risk Factor for Atrial Fibrillation among the Taiwanese
por: Hsiao, Fu-Chih, et al.
Publicado: (2016)

Microsatellite Polymorphism in the Heme Oxygenase-1 Gene Promoter and the Risk of Atrial Fibrillation in Taiwanese
por: Hsu, Lung-An, et al.
Publicado: (2014)

Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban
por: Chao, Tze-Fan, et al.
Publicado: (2022)

Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study
por: Lee, Kuang-Tso, et al.
Publicado: (2017)

Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study
por: Lee, Hsin-Fu, et al.
Publicado: (2016)

Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies
por: Chang, Shang-Hung, et al.
Publicado: (2014)

Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study
por: Tung, Ying-Chang, et al.
Publicado: (2021)

Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study
por: Wu, Hsin-Hsu, et al.
Publicado: (2022)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
por: Chen, Hsin-Hung, et al.
Publicado: (2019)

Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan
por: Shen, Cheng-Huang, et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study
por: Lai, Yun-Ju, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study
por: Chen, Yi-Chuan, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitor Decreases Abdominal Aortic Aneurysm Formation through GLP-1-Dependent Monocytic Activity in Mice
por: Lu, Hsin Ying, et al.
Publicado: (2015)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin, Yi-Hsin, et al.
Publicado: (2019)

Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
por: Chen, Kuan-Chan, et al.
Publicado: (2020)

A Novel DES L115F Mutation Identified by Whole Exome Sequencing is Associated with Inherited Cardiac Conduction Disease
por: Hsu, Lung-An, et al.
Publicado: (2019)

Genetic variants of dipeptidyl peptidase IV are linked to the clinicopathologic development of prostate cancer
por: Wen, Yu‐Ching, et al.
Publicado: (2023)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Ling, Ann Wan-Chin, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
por: Hung, Chih-Tsung, et al.
Publicado: (2022)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

miR-181b targets semaphorin 3A to mediate TGF-β–induced endothelial-mesenchymal transition related to atrial fibrillation
por: Lai, Ying-Ju, et al.
Publicado: (2022)

Traumatic Brain Injury and Substance Related Disorder: A 10-Year Nationwide Cohort Study in Taiwan
por: Wu, Chieh-Hsin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gimldbgmtc577ht2q3ag9u7sk9